VIR-2482
Seasonal Influenza Prophylaxis
Phase 2Active (PREVENT study)
Key Facts
Indication
Seasonal Influenza Prophylaxis
Phase
Phase 2
Status
Active (PREVENT study)
Company
About Vir Biotechnology
Vir Biotechnology is a San Francisco-based immunology company with a mission to power the immune system to transform patient lives. Founded in 2016, the company has rapidly validated its technology platforms through successful COVID-19 and Ebola programs and is now strategically focused on high-unmet-need areas, including chronic hepatitis delta and select oncology indications. Its strategy combines deep immunology expertise with advanced antibody engineering to create differentiated, rapidly deployable clinical candidates.
View full company profile